Stay Informed With Our Latest Updates

Client Alert January 12, 2026

Life Sciences 2026 Outlook

The life sciences industry enters 2026 with a constructive set of tailwinds, following a second half of 2025 in which dealmaking activity showed clearer signs of normalization after a prolonged slowdown. While risks remain, particularly around geopolitics, trade policy, and regulatory priorities, the overall setup for 2026 is cautiously constructive, with improved visibility into execution pathways for well-positioned assets and platforms.

Royalty Finance Tracker

The Gibson Dunn team has represented clients in royalty finance transactions with a total aggregate value of approximately $8 Billion.

Firm News November 14, 2025

Gibson Dunn Advising Merck on $9.2 Billion Acquisition of Cidara Therapeutics

Gibson Dunn is advising Merck on its $9.2 billion acquisition of Cidara Therapeutics, Inc., a biotechnology company developing drug-Fc conjugate (DFC) therapeutics

Accolades October 3, 2025

Gibson Dunn Earns Multiple Recognitions in LMG Life Sciences 2025

The 2025 edition of LMG Life Sciences recognized Gibson Dunn for excellence in the following six practice areas

Firm News September 19, 2025

Gibson Dunn Advises 89bio on Its up to $3.5 Billion Sale to Roche Holdings

Gibson Dunn is advising 89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, on its up to $3.5 billion sale to Roche Holdings, Inc.

Accolades September 5, 2025

Gibson Dunn a Four-Time Winner at LMG Life Sciences Americas Awards 2025

Gibson Dunn was honored with four awards at the 13th annual LMG Life Sciences Americas Awards, presented in New York City on September 4

Firm News September 4, 2025

Gibson Dunn Advises Arrowhead Pharmaceuticals on Global Licensing and Collaboration Agreement with Novartis

Gibson Dunn is advising Arrowhead Pharmaceuticals on its global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s preclinical-stage siRNA therapy targeting alpha-synuclein for the treatment of synucleinopathies, as well as for additional collaboration targets utilizing Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform

Firm News August 26, 2025

Gibson Dunn Advises Royalty Pharma on Acquisition of Royalty Interest in Amgen’s Imdelltra

Gibson Dunn is representing Royalty Pharma plc in its acquisition of a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for up to $950 million.